Incyte Corporation vs ING Groep NV — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while ING Groep NV trades at $32.22 (market cap $92.65B). The key difference: ING Groep NV is far larger — about 4× Incyte Corporation's market cap, and ING Groep NV pays a 3.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ING | |
|---|---|---|
Market Cap | $23.11B | $92.65B |
Sector | Health | Financials |
52-Week High | $118.52 | $33.31 |
52-Week Low | $67.38 | $22.71 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 3.93% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →